Expert opinion on pharmacotherapy · 2026
Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de la Peña Ike, Row Justin, Shi Wei-Xing
Аннотация
INTRODUCTION: Stimulant use disorder (StUD), including cocaine and methamphetamine use disorders, remains a major unmet clinical need with no approved pharmacotherapies. Despite strong mechanistic rationale, dopamine transporter (DAT)-directed strategies have largely failed to translate into consistent clinical benefit.
AREAS COVERED: This review evaluates the contemporary pharmacotherapy landscape for StUD, focusing on phase II/III clinical trials and systematic reviews published from January 2020- April 2026. Evidence was identified through PubMed/MEDLINE and ClinicalTrials.gov and synthesized narratively due to study heterogeneity. Therapeutic approaches are organized by mechanistic class, including DAT-targeting agents, non-DAT strategies (multi-monoaminergic, glutamatergic, serotonergic, and neuroimmune), and combination pharmacotherapy. Across studies, monotherapies generally demonstrate limited or inconsistent efficacy, although mirtazapine has shown the most consistent positive findings. Combination pharmacotherapy approaches, particularly naltrexone-bupropion, have generated some of the most encouraging clinical results to date. The role of DAT is reappraised within emerging biological frameworks and a systems-level model of addiction.
EXPERT OPINION: Current evidence supports a reappraisal of DAT as one component of a broader neurobiology of stimulant addiction. Future therapeutic development may benefit from moving beyond DAT-centric strategies toward integrated, multi-target approaches. Combination pharmacotherapy represents a promising direction for investigation, although available evidence remains heterogeneous and requires substantial clinical validation.
AREAS COVERED: This review evaluates the contemporary pharmacotherapy landscape for StUD, focusing on phase II/III clinical trials and systematic reviews published from January 2020- April 2026. Evidence was identified through PubMed/MEDLINE and ClinicalTrials.gov and synthesized narratively due to study heterogeneity. Therapeutic approaches are organized by mechanistic class, including DAT-targeting agents, non-DAT strategies (multi-monoaminergic, glutamatergic, serotonergic, and neuroimmune), and combination pharmacotherapy. Across studies, monotherapies generally demonstrate limited or inconsistent efficacy, although mirtazapine has shown the most consistent positive findings. Combination pharmacotherapy approaches, particularly naltrexone-bupropion, have generated some of the most encouraging clinical results to date. The role of DAT is reappraised within emerging biological frameworks and a systems-level model of addiction.
EXPERT OPINION: Current evidence supports a reappraisal of DAT as one component of a broader neurobiology of stimulant addiction. Future therapeutic development may benefit from moving beyond DAT-centric strategies toward integrated, multi-target approaches. Combination pharmacotherapy represents a promising direction for investigation, although available evidence remains heterogeneous and requires substantial clinical validation.